Why the study?
Does screening with brain natriuretic peptide (BNP) detect structural heart disease in asymptomatic patients with Type 2 diabetes mellitus?
Does screening with brain natriuretic peptide (BNP) detect structural heart disease in asymptomatic patients with Type 2 diabetes mellitus?
BNP testing is proposed as a simple, inexpensive screening tool to detect asymptomatic structural heart disease in patients with Type 2 diabetes mellitus and prioritize echocardiography referral.
Cardiovascular disease is the leading cause of death among patients with Type 2 diabetes mellitus. The main forms of structural heart disease associated with diabetes are coronary heart disease and diabetic cardiomyopathy, which is characterized by left ventricular hypertrophy, left ventricular diastolic and systolic dysfunction. Asymptomatic structural heart disease is common and associated with a poor prognosis in patients with diabetes. Contemporary practice guidelines do not recommend screening of asymptomatic individuals for structural heart disease. Potential screening modalities, such as echocardiography, are costly and inaccessible. A simple, inexpensive blood test for brain natriuretic peptide is a useful marker of structural heart disease and is a prime candidate for screening patients with Type 2 diabetes mellitus and prioritizing referral for echocardiography.
No takes yet. Share an insight, caveat, or question.
Somaratne et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: